WALTHAM, Mass., July 20, 2017 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that its second quarter 2017 financial results will be released on Thursday, August 3, 2017 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.
Dial-in Number
U.S./Canada Dial-in Number: (877) 412-6083
International Dial-in Number: (702) 495-1202
Conference ID: 36834416
Replay Dial-in Number: (855) 859-2056
Replay International Dial-in Number: (404) 537-3406
Conference ID: 36834416
A telephone replay will be available from approximately 11:00 a.m. ET on August 3, 2017 through midnight on August 9, 2017.
The webcast with slides will be accessible through the Investors section of the company’s website at www.amagpharma.com. A replay of the webcast will be archived on the website for 30 days.
About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of maternal and women’s health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc. CBR® is a registered trademark of Cbr Systems, Inc.
AMAG Pharmaceuticals Contact: Christi Waarich Associate Director, Investor Relations 617-498-7638


Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
Britain Courts Anthropic Amid US Defense Department Dispute
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover
UPS and Teamsters Reach Agreement to Limit Driver Severance Program
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
First Western Ship Transits Strait of Hormuz Since Iran War Began
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 



